Modern approaches to pharmacotherapy of chronic gastritis

The definition of gastritis is based on the histological features of the gastric mucosa. This is not the erythema observed during gastroscopy, and there are no specific clinical manifestations or symptoms that determine it. The modern classification of gastritis is based on time (acute and chronic), histological features, anatomical distribution and the main pathological mechanisms. Acute gastritis will develop into chronic if left untreated. Helicobacter pylori (H. pylori) is the most common cause of gastritis worldwide. However, from 60 to 70% H. pylori-negative subjects with functional dyspepsia or non-erosive gastroesophageal reflux were also found to have gastritis. H. pylori-negative gastritis is considered when a person meets all four of these criteria: negative triple staining of biopsies of the gastric mucosa, no history of treatment of H. pylori. In these patients, the cause of gastritis may be associated with tobacco smoking, alcohol consumption and / or the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids. Other causes of gastritis include autoimmune gastritis associated with antibodies of serum anti-parietal and anti-internal factor; organisms other than H. pylori, such as Mycobacterium avium intracellulare, Herpes simplex and Cytomegalovirus; gastritis caused by acid reflux; Rare causes of gastritis include collagen gastritis, sarcoidosis, eosinophilic gastritis and lymphocytic gastritis. The clinical picture, laboratory studies, gastroscopy, as well as histological and microbiological examination of tissue biopsies are important for the diagnosis of gastritis and its causes. Treatment of gastritis caused by H. pylori leads to the rapid disappearance of polymorphic-nuclear infiltration and a decrease in chronic inflammatory infiltrate with gradual normalization of the mucous membrane. Other types of gastritis should be treated based on their etiology.

1. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 2014;61:1–241. Available at: https://pubmed.ncbi.nlm.nih.gov/7715068/.

2. Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis – an update. Best Pract Res Clin Gastroenterol. 2014;28(6):1031–1042. https://doi.org/10.1016/j.bpg.2014.10.005.

3. Bacha D., Walha M., Ben Slama S., Ben Romdhane H., Bouraoui S., Bellil K. et al. Chronic gastritis classifications. Tunis Med. 2018;96(7):405–410. https://www.latunisiemedicale.com/article-medicale-tunisie.php?article=3412.

4. Telaranta-Keerie A., Kara R., Paloheimo L., Härkönen M., Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol. 2010;45(9):1036–1041. https://doi.org/10.31 09/00365521.2010.487918.

5. Lahner E., Zagari R.M., Zullo A., Di Sabatino A., Meggio A., Cesaro P. et al. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig Liver Dis. 2019;51(12):1621–1632. https://doi.org/10.1016/j.dld.2019.09.016.

6. Fang J.Y., Du Y.Q., Liu W.Z., Ren J.L., Li Y.Q., Chen X.Y. et al. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis. 2018;19(4):182–203. https://doi.org/10.1111/1751-2980.12593.

7. Sabbagh P., Javanian M., Koppolu V., Vasigala V.R., Ebrahimpour S. Helicobacter pylori infection in children: an overview of diagnostic methods. Eur J Clin Microbiol Infect Dis. 2019;38(6):1035–1045. https://doi. org/10.1007/s10096-019-03502-5.

8. Rugge M., Sugano K., Scarpignato C., Sacchi D., Oblitas W.J., Naccarato A.G. Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter. 2019;24(2):e12571. https://doi.org/10.1111/hel.12571.

9. Honarmand-Jahromy S., Siavoshi F., Malekzadeh R., Nejad Sattari T., LatifiNavid S. Reciprocal impact of host factors and Helicobacter pylori genotypes on gastric diseases. World J Gastroenterol. 2015;21(31):9317–9327. https://doi.org/10.3748/wjg.v21.i31.9317.

10. Chitapanarux T., Jesadaporn P., Chitapanarux N., Lertprasertsuke N. Chronic gastritis according to age and Helicobacter pylori in Thailand: histopathological patterns. Scand J Gastroenterol. 2021;56(3):228–233. https://doi.org/ 10.1080/00365521.2020.1869820.

11. Rugge M., Genta R.M., Fassan M., Valentini E., Coati I., Guzzinati S. et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Longterm Follow-up Study of 7436 Patients. Am J Gastroenterol. 2018;113(11):1621–1628. https://doi.org/10.1038/s41395-018-0353-8.

12. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr. 2016;166(13–14):424–430. https://doi.org/10.1007/s10354-016-0515-5.

13. Pennelli G., Grillo F., Galuppini F., Ingravallo G., Pilozzi E., Rugge M. et al. Gastritis: update on etiological features and histological practical approach. Pathologica. 2020;112(3):153–165. https://doi.org/10.32074/1591-951X-163.

14. Zhu J.Y., Zhai H.H., Li P. Diagnosis and follow-up of chronic atrophic gastritis. Zhonghua Nei Ke Za Zhi. 2020;59(1):71–74. https://doi.org/10.3760/cma.j.is sn.0578-1426.2020.01.013.

15. Lenti M.V., Rugge M., Lahner E., Miceli E., Toh B.H., Genta R.M. et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6(1):56. https://doi. org/10.1038/s41572-020-0187-8.

16. Cellini M., Santaguida M.G., Virili C., Capriello S., Brusca N., Gargano L., Centanni M. Hashimoto’s Thyroiditis and Autoimmune Gastritis. Front Endocrinol (Lausanne). 2017;8:92. https://doi.org/10.3389/fendo.2017.00092.

17. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. https://doi.org/10.1136/gutjnl-2015-309252.

18. Tsuboi M., Niikura R., Hayakawa Y., Hirata Y., Ushiku T., Koike K. Distinct Features of Autoimmune Gastritis in Patients with Open-Type Chronic Gastritis in Japan. Biomedicines. 2020;8(10):419. https://doi.org/10.3390/ biomedicines8100419.

19. Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H. et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. BMC Gastroenterol. 2016;16(1):119. https://doi.org/10.1186/s12876-016-0532-2.

20. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/ gutjnl-2016-312288.

21. Minushkin O.N., Zverkov I.V., Lvova N.V., Skibina Y.S., Inevatova V.S. Chronic gastrite: modern state of the problem. Terapevticheskii arkhiv = Therapeutic Archive. 2020;92(8):18–23. (In Russ.) https://doi.org/10.26442/00403660.2 020.08.000693.

22. Kim W.S., Kim W.K., Choi N., Suh W., Lee J., Kim D.D. et al. Development of S-Methylmethionine Sulfonium Derivatives and Their Skin-Protective Effect against Ultraviolet Exposure. Biomol Ther (Seoul). 2018;26(3):306– 312. https://doi.org/10.4062/biomolther.2017.109.

23. Gezginci-Oktayoglu S., Turkyilmaz I.B., Ercin M., Yanardag R., Bolkent S. Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties. Protoplasma. 2016;253(1):127–135. https://doi.org/10.1007/s00709-015-0796-3.

24. Kruchinina T.V., Makhova A.A., Shikh E.V., Drozdov V.N. S-methylmethionin (vitamin U): experimental studies and clinical perspective. Voprosy pitaniia = Problems of Nutrition. 2018;87(5):70–76. (In Russ.) https://doi.org/10.24411/0042-8833-2018-10055.

25. Patel A.D., Prajapati N.K. Review on biochemical importance of vitamin-U. J Chem Pharm Res. 2012;4(1):209–215. Available at: https://www.jocpr. com/articles/review-on-biochemical-importance-of-vitaminu.pdf.

26. Lee N.Y., Park K.Y., Min H.J., Song K.Y., Lim Y.Y. et al. Inhibitory Effect of Vitamin U (S-Methylmethionine Sulfonium Chloride) on Differentiation in 3T3-L1 Pre-adipocyte Cell Lines. Ann Dermatol. 2012;24(1):39–44. https://doi.org/10.5021/ad.2012.24.1.39.